Story perspectives

U.S. Aims to Protect 2M from HIV with Lenacapavir

9/7/2025

Summary

U.S. Promotes HIV Prevention

The U.S. supports lenacapavir, an HIV prevention drug, aiming to reach 2 million people by 2028.
Backed by PEPFAR and the Global Fund, the initiative targets mother-to-child transmission prevention.
Lenacapavir requires biannual injections and demonstrated nearly complete protection in trials.
Gilead Sciences will provide the drug at no profit, estimated at $100 per person annually.
Activists raise concerns about funding cuts impacting PEPFAR's effectiveness.

Summary

Advocates Fight Funding Cuts

Advocates gathered on Capitol Hill to oppose proposed cuts to HIV funding during the U.S. Conference on HIV/AIDS.
U.S. Rep. Maxine Waters expressed distrust in Health Secretary Robert F. Kennedy, Jr.'s commitment to HIV funding.
Activist Javier Muñoz highlighted the importance of federally funded programs for accessing life-saving medications.
Peppermint warned that funding cuts could undo decades of progress in HIV treatment and prevention.
Harold Phillips urged unity to protect healthcare access for vulnerable populations.

1 of 2

U.S. Promotes HIV Prevention

The U.S. supports lenacapavir, an HIV prevention drug, aiming to reach 2 million people by 2028.
Backed by PEPFAR and the Global Fund, the initiative targets mother-to-child transmission prevention.
Lenacapavir requires biannual injections and demonstrated nearly complete protection in trials.
Gilead Sciences will provide the drug at no profit, estimated at $100 per person annually.
Activists raise concerns about funding cuts impacting PEPFAR's effectiveness.

1 / 2